- Thoughts from around the web: using ‘Most Favored Nation’ for US Drug Pricingby Jason Shafrin (Healthcare Economist) on May 16, 2025
Lakdawalla and Goldman. Tyler Cowen. AARP. National Pharmaceutical Council (from 2021) BIO. Adam Fein Here is a comparison of the CMS Final Rule (from 2021) vs. 2025 Trump Executive Order.
- What are concerns with IRA drug price negotiations for part B drugs?by Jason Shafrin (Healthcare Economist) on May 16, 2025
There were lots of very interesting sessions at ISPOR 2025 in Montreal. One of my favorites that I was able to attend was titled “Medicare Price Negotiation of Part B Drugs: Implications for Provider Reimbursement and Commercial Spillover“. The […]
- How does hospital participation in a Medicare Advantage preferred network impact commercial reimbursement?by Jason Shafrin (Healthcare Economist) on May 15, 2025
How does a hospital’s participation in a health plan’s Medicare Advantage (MA) provider network impact their commercial rates? Since many insurers offer both MA plans and commercial plans, there could be spillovers with respect to negotiating. […]
- How do drug prices change before loss of exclusivity?by Jason Shafrin (Healthcare Economist) on May 14, 2025
Typically, cost effectiveness analyses assume a constant price between drug approvals and loss of exclusivity. It is not clear, however, to what extent that assumption is valid, particularly after taking into account drug price discounts and […]
- Linksby Jason Shafrin (Healthcare Economist) on May 8, 2025
I’ll be at ISPOR. Health Care Subscriptions: Who Benefits and Who Gets Left Behind? NIH bans new funding from US scientists to scientists abroad Most favored nation. CDC: RSV vaccine works.
- Will the Trump Administration implement a Most Favored Nation policy for US drug prices?by Jason Shafrin (Healthcare Economist) on May 7, 2025
Perhaps so according to Politico: Trump early next week is expected to sign an executive order directing aides to pursue the initiative, called “most favored nation,” for a selection of drugs within the Medicare program. The idea would use the […]
- Do Medicare Advantage plans with high medication adherence rates do well on Medicare Advantage Star ratings?by Jason Shafrin (Healthcare Economist) on May 7, 2025
The answer is ‘yes’ according to a paper by Borrelli et al. (2025). The authors use annual Medicare Star Rating health plan performance for Medicare Advantage-Part D (MAPD) plans over the past decade (2015 to 2024). They find that: For plans […]
- Why is Affordable housing so expensive?by Jason Shafrin (Healthcare Economist) on May 6, 2025
From Coby Lefkowitz in Building Optimism: In Los Angeles, “luxury” units in non-high-rises can be delivered for around $300,000 to $400,000 per unit. Non-“luxury” market rate units can be completed for half of that, conditional on their size […]
- ISPOR 2025 in Montréalby Jason Shafrin (Healthcare Economist) on May 5, 2025
Three panels. One great city. Can’t wait for the conversations at ISPOR 2024 in Montréal. GCEA: Where do we go from here? (14 May, 5-6pm) Should we finally rethink the 3% discount rate? (15 May, 3:15-4:15pm) How can HEOR support providers in […]
- Linksby Jason Shafrin (Healthcare Economist) on May 2, 2025
Innovative Payment Models for Sickle-Cell Disease Gene Therapies. EHR records transfer: fax, CD, mail. ‘Why public health must always be led by economists’ Impact of federal cuts and inflation on food banks. End of an era?